This site is using cookies. Privacy Policy.

Fujifilm Irvine Scientific Locates Biopharmaceutical Manufacturing Facility in the Netherlands

New bioproduction center for cell culture media will be a hub to serve European customers

Fujifilm Irvine Scientific announces biopharmaceutical Manufacturing site in the Netherlands

Fujifilm Irvine Scientific, the U.S.-based global leader in the innovation, development, and manufacturing of cell culture media, has announced plans to open a third biopharmaceutical manufacturing facility in Tilburg, the Netherlands. The company currently has sites in the United States and Japan. The world-class cGMP manufacturing facility will serve as a European hub and enable the company to better provide customers with a rapid, reliable supply of products.

Fujifilm’s investment in the project demonstrates its commitment to accelerate development in bioproduction and, cell and gene therapy markets, the company stated.

By locating in the Netherlands, the company becomes part of the highly-concentrated and diversified Dutch Life Sciences and Health community.

Specialized biopharmaceuticals

The facility will occupy a 23,225 square meter building within Fujifilm Manufacturing Europe, one of the largest Fujifilm production centers outside of Japan. The space will support cGMP manufacturing of animal component-free, dry powder media, liquid media, and downstream bioprocessing liquids, thereby adding additional production capacity for Fujifilm Irvine Scientific of 320,000 Kg/year for dry powder, and 470,000 L/year for liquids. Water for Injection (WFI) will also be manufactured on the premises.

Cell therapy

“The biopharmaceutical market is growing at a high rate, and cell therapies are moving into clinical trials and commercialization at fast pace,” said Yutaka Yamaguchi, CEO of Fujifilm Irvine Scientific. “The company’s current capacity is >1,000,000 Kg/year of dry powder, but it is imperative that we exceed production requirements of customers worldwide, as well as meet our European customer demand for regional support.”

Work on the new manufacturing site has begun and it is expected to be commissioned in the second half of 2021.

About Fujifilm Irvine Scientific

Fujifilm Irvine Scientific Inc. is a worldwide leader in the innovation and manufacturing of cell culture media, reagents, and medical devices for researchers and clinicians. The company serves scientists working in biopharmaceuticals, cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. Fujifilm Irvine Scientific, Inc. is a subsidiary of Fujifilm Holdings America Corporation reporting to FUJIFILM Holdings Corporation in Tokyo, Japan.

Source: Fujifilm Irvine Scientific

5 July 2019

Get In Touch

Contact Us